Rationale: Sibutramine (Meridia) is a serotonin and norepinephrine reuptake
inhibitor marketed for weight control. Previous studies demonstrated low a
buse potential for 20 and 30 mg sibutramine (doses near the therapeutic ran
ge). however, no data existed on supra-therapeutic doses. This study, there
fore, examined 25 and 75 mg sibutramine in humans compared to d-amphetamine
(20 mg) as a positive control and placebo as a negative control. Ojectives
: The study examined the acute subjective, reinforcing, and physiological e
ffects of sibutramine to assess its abuse liability. Methods: Twelve polydr
ug abusers with no history of drug dependence participated in this double-b
lind, inpatient/outpatient study. Volunteers participated in four drug sess
ions, in which they completed subjective effects scales including the Profi
le of Mood States (POMS), Visual Analog Scales (VAS), and the Addiction Res
earch Center Inventory (ARCI). The Multiple Choice Procedure (MCP) was used
to evaluate reinforcing efficacy. Results: Sibutramine 25 mg produced subj
ective effects that were indistinguishable from placebo. Sibutramine 75 mg
produced significant unpleasant effects, such as Anxiety, Confusion, and de
creased Vigor. On the MCP, volunteers chose to give up an average of $4.04
from their study pay rather than receive the higher dose of sibutramine aga
in. In contrast, d-amphetamine 20 mg produced positive mood changes and was
well liked. Conclusions: These data indicate sibutramine lacks amphetamine
-type abuse liability when administered acutely.